Yahoo Finance 
Stocks In Focus SG (Hiap Tong, IHH, LottVision) – 29/05/15
Hiap Tong Corporation announced a 44.5 percent fall in FY15 net profit to $2.2 million. Revenue decreased 16.2 percent to $38.3 million due to a decrease in leasing income. An oversupply of cranes in the industry led to increased competition and lower leasing rates. The impact was partially cushioned by a $1.4 million increase in other income due to net gains on disposal of equipment and insurance claims. Going forward, the group expects the business environment to remain competitive due to the current over supply of cranes coupled with a general decline in demand from customers. The group’s trading business is also expected to be weak for the current financial year.
IHH Healthcare’s 1Q15 top line grew 14 percent to RM2,003 million due to organic growth of existing operations as well as the commencement of operations of two new hospitals in 2014. Staff costs increased by RM124.2 million, due to increased headcount and higher salary driven by the demand for trained healthcare professionals. The group posted net profit of RM171.5 million, representing a 7.8 percent increase from RM159.1 million in 1Q14. Going forward, the group expects to have sufficient capacity to meet increased demand for quality private healthcare across its home markets through the expansion of facilities and opening of new ones. This is expected to bring the total number of beds to over 10,000 beds by 2017.
LottVision reported a net profit of HK$1.3 million for FY15, down 6.9 percent from HK$1.4 million in FY14. Revenue expanded by 9.5 percent to HK$99.8 million largely contributed by the group’s 55 percent interest in Nutryfarm (Chengdu) Biomedicine (NFC). Distribution expenses increased by HK$12.5 million attributed to higher advertising and marketing activities, partially offsetting the revenue growth. Going forward, NFC targets to achieve at least 10 approvals of new products in FY16. As part of its current marketing strategy, NFC is planning to enter over 100 supermarkets in China, expecting to increase its revenue extremely in FY16.
More From Shares Investment:
